A Response to: Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis”

Abstract

We would like to thank you for allowing us the opportunity to respond to the letter received from Marshall et al. and to address the queries raised with respect to our network meta-analysis (NMA) of fluticasone furoate/umeclidinium/ vilanterol (FF/UMEC/VI) triple therapy compared with other therapies for the treatment of chronic obstructive pulmonary disease (COPD) [1].To minimize clinical heterogeneity across COPD studies, we conducted two separate NMAs [1,2] and presented the data in parallel in the same journal. The dual therapy NMA [2] included studies from patients who were mostly symptomatic with infrequent exacerbations to ensure that the long-acting b 2 -agonist (LABA)/ long-acting muscarinic antagonist (LAMA) A. S. Ismaila (&) Value Evidence and Outcomes, GSK,